Rhenman & Partners Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-244,000	Closed	-$5.77M	–	103
2019 Q3	$5.77M	Buy	244,000 +15,000	+7%	+$445K	0.72%	52
2019 Q2	$6.89M	Buy	229,000 +79,000	+53%	+$1.81M	0.76%	52
2019 Q1	$3.36M	Buy	+150,000	New	+$3.22M	0.39%	65
2018 Q2	–	Sell	-39,115	Closed	-$208K	–	93
2018 Q1	$208K	Sell	39,115 -69,336	-64%	-$496K	0.03%	92
2017 Q4	$922K	Sell	108,451 -11,246	-9%	-$138K	0.12%	81
2017 Q3	$1.75M	Buy	+119,697	New	+$1.81M	0.22%	77

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rhenman & Partners Asset Management's RARX Position: Q4 2019 in Review

Rhenman & Partners Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 244,000 shares — an estimated $5.77M sold.

Rhenman & Partners Asset Management first reported a position in RARX in Q3 2017 and held it in 6 quarters. The position peaked at $6.89M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Rhenman & Partners Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Rhenman & Partners Asset Management sold 244,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $5.77M.
Rhenman & Partners Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 6 quarters.
Rhenman & Partners Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $6.89M in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.